NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
Latest Information Update: 07 Jun 2023
At a glance
- Drugs Durvalumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NVALT28
- 06 Dec 2021 Planned End Date changed from 1 Apr 2028 to 1 Dec 2032.
- 06 Dec 2021 Planned primary completion date changed from 1 Apr 2028 to 1 Dec 2028.
- 06 Dec 2021 Status changed from not yet recruiting to recruiting.